Abbott Laboratories (ABT) |
|
|
|
Abbott Laboratories Income Statement Annual
ABT
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
INCOME STATEMENT (Annual GAAP In millions $) |
(Dec 31 2011) 2011 |
(FY 2010) (Dec. 31. 2010) |
(FY 2009) (Dec. 31. 2009) |
(FY 2008) (Dec. 31. 2008) |
(FY 2007) (Dec. 31. 2007) |
Revenue From Contract With Customer Excluding Assessed Tax |
38,851.00 |
30,765.00 |
30,765.00 |
29,527.55 |
25,914.24 |
Revenue From Contract With Customer Excluding Assessed Tax |
- |
- |
- |
- |
- |
Total Revenue |
38,851.00 |
30,765.00 |
30,765.00 |
29,527.55 |
25,914.24 |
Cost of Goods and Services Sold |
15,541.00 |
13,209.00 |
13,209.00 |
12,612.02 |
11,422.05 |
Gross
Profit |
23,310.00 |
17,556.00 |
17,556.00 |
16,915.53 |
14,492.19 |
Selling, Administration, Marketing |
12,756.00 |
8,406.00 |
8,406.00 |
8,435.62 |
7,408.00 |
Depriciation & Amortization |
- |
- |
- |
- |
- |
Research and Development Expense |
4,802.00 |
2,914.00 |
2,914.00 |
2,786.07 |
2,505.65 |
Restructuring charges |
- |
- |
- |
- |
- |
Other exp. /-income |
- |
- |
- |
- |
- |
Special Items |
- |
- |
- |
- |
- |
Total operating costs including COS |
33,099.00 |
24,529.00 |
24,529.00 |
23,833.71 |
21,335.69 |
Operating income/-loss
|
5,752.00 |
6,236.00 |
6,236.00 |
5,693.84 |
4,578.55 |
Other Deductions / - Income |
Interest expense |
445.00 |
382.00 |
382.00 |
327.25 |
456.39 |
Interest income |
- |
- |
- |
- |
- |
Net interest expense/-income |
445.00 |
382.00 |
382.00 |
327.25 |
456.39 |
Investment Income, Interest |
- |
- |
- |
- |
- |
Foreign Currency Transaction Gain (Loss), before Tax |
- |
- |
- |
-119.00 |
-498.02 |
Sale of Assets |
- |
- |
- |
- |
- |
Financing Loss/ -Income |
-50.00 |
35.00 |
35.00 |
84.24 |
15.00 |
Other loss/ -income |
158.00 |
-1,375.00 |
-1,375.00 |
-454.94 |
135.53 |
Total costs & expenses |
33,652.00 |
23,571.00 |
23,571.00 |
23,671.27 |
21,444.59 |
Income /-loss before income taxes |
5,199.00 |
7,194.00 |
7,194.00 |
5,856.29 |
4,469.65 |
Income taxes expenses/-benefit |
470.00 |
1,448.00 |
1,448.00 |
1,122.07 |
863.33 |
Income after income taxes |
4,729.00 |
5,746.00 |
5,746.00 |
4,734.22 |
3,606.31 |
Net income/-loss
of other equity |
- |
- |
- |
- |
- |
Income/-loss
from cont. Ops. |
4,729.00 |
5,746.00 |
5,746.00 |
4,734.22 |
3,606.31 |
Accounting change |
- |
- |
- |
- |
- |
Discontinued operations |
- |
- |
- |
146.50 |
- |
Extraordinary items |
- |
- |
- |
- |
- |
Net Income/-loss |
4,729.00 |
5,746.00 |
5,746.00 |
4,880.72 |
3,606.31 |
Noncontrolling interests |
- |
- |
- |
- |
- |
Prefered dividends |
- |
- |
- |
- |
- |
Other |
- |
- |
- |
- |
- |
Income/-loss to shareholder |
4,729.00 |
5,746.00 |
5,746.00 |
4,880.72 |
3,606.31 |
EBIT |
5,644.00 |
7,576.00 |
7,576.00 |
6,183.53 |
4,926.04 |
EBITD |
7,039.37 |
8,783.45 |
8,786.98 |
7,235.26 |
5,998.89 |
EBITDA |
8,687.89 |
10,200.31 |
9,665.51 |
8,022.36 |
6,780.92 |
Per
Share (GAAP Annual, in $) |
(Dec 31 2011) 2011 |
(FY 2010) (Dec. 31. 2010) |
(FY 2009) (Dec. 31. 2009) |
(FY 2008) (Dec. 31. 2008) |
(FY 2007) (Dec. 31. 2007) |
Basic EPS (excl. extra
items) |
3.01 |
2.96 |
3.69 |
3.03 |
2.31 |
Extraordinary items |
0.00 |
0.00 |
0.00 |
0.09 |
0.00 |
Basic Net EPS |
3.01 |
2.96 |
3.69 |
3.12 |
2.31 |
Basic shares outstanding (Mill.
of Units) |
1,567.00 |
1,556.00 |
1,555.00 |
1,560.75 |
1,560.06 |
EPS other shares |
- |
- |
- |
- |
- |
Diluted Net EPS |
3.01 |
2.96 |
3.69 |
3.12 |
2.31 |
Diluted average shares (Mill.
of Units) |
1,567.00 |
1,556.00 |
1,555.00 |
1,560.75 |
1,560.06 |
Dividend per share |
1.87 |
1.72 |
1.55 |
1.39 |
1.26 |
|
|